

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 14, 2002, 09:40:13 ; Search time 30.46 Seconds

(without alignments)
466.758 Million cell updates/sec

Title: US-09-684-215a-18

Perfect score: 653

Sequence: 1 TAAADNFQSLQSGGFAIP.....QTKSGTFRGNTVLAEGPPA 128

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Genesec_032802:*

1: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1980.DAT:*
2: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1981.DAT:*
3: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1982.DAT:*
4: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1983.DAT:*
5: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1984.DAT:*
6: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1985.DAT:*
7: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1986.DAT:*
8: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1987.DAT:*
9: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1988.DAT:*
10: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1989.DAT:*
11: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1990.DAT:*
12: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1991.DAT:*
13: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1992.DAT:*
14: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1993.DAT:*
15: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1994.DAT:*
16: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1995.DAT:*
17: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1996.DAT:*
18: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1997.DAT:*
19: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA1998.DAT:*
20: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA2000.DAT:*
21: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA2001.DAT:*
22: /SIDSL/gcgdata/hold-genesecq/genesecp-emb1/AA2001.DAT:*

Pried. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	653	100.0	224	22	AAU69899	Human prostate pro
2	653	100.0	224	22	AAU69902	Ra12-P510S-C const
3	653	100.0	304	22	AAU69902	Human /M. tubercul
4	653	100.0	304	22	AAU69907	Ra12-P775P-ORF3 co
5	653	100.0	400	22	AAU69907	Human prostate pro
6	653	100.0	400	22	AAU69907	Ra12-P501S-E2 cons
7	653	100.0	487	22	AAU69907	Chlamydia trachoma
8	653	100.0	518	22	AAU69907	Chlamydia trachoma
9	653	100.0	525	21	AAU69907	C. pneumoniae sero
10	653	100.0	525	22	AAU69907	Protein encoded by
11	653	100.0	583	22	AAU69907	Chlamydia trachoma

12	653	100.0	585	22	AAU69907	Chlamydia trachoma
13	653	100.0	619	22	AAU69907	Chlamydia trachoma
14	653	100.0	631	22	AAU69907	Chlamydia trachoma
15	653	100.0	646	22	AAU69907	Chlamydia trachoma
16	653	100.0	654	22	AAU69907	Chlamydia trachoma
17	653	100.0	683	22	AAU69907	Chlamydia trachoma
18	653	100.0	691	22	AAU69907	Chlamydia trachoma
19	653	100.0	700	22	AAU69907	Chlamydia trachoma
20	653	100.0	715	22	AAU69907	Chlamydia trachoma
21	653	100.0	715	22	AAU69907	Chlamydia trachoma
22	653	96.8	231	20	AAU69907	Mycobacterium spec
23	653	96.8	355	20	AAU69907	Mycobacterium spec
24	653	96.8	355	22	AAU69907	Mycobacterium spec
25	653	96.8	379	20	AAU69907	M. tuberculosis an
26	653	96.8	543	22	AAU69907	M. tuberculosis an
27	653	96.8	729	22	AAU69907	Mycobacterium tube
28	653	96.0	132	18	AAU69907	Mycobacterium tube
29	653	96.0	132	18	AAU69907	M. tuberculosis im
30	653	96.0	132	19	AAU69907	Mycobacterium tube
31	653	96.0	132	19	AAU69907	M. tuberculosis an
32	653	96.0	132	20	AAU69907	M. tuberculosis an
33	653	96.0	132	20	AAU69907	Mycobacterium tube
34	653	96.0	132	22	AAU69907	Mycobacterium tube
35	653	96.0	132	22	AAU69907	Mycobacterium tube
36	653	96.0	132	22	AAU69907	Mycobacterium tube
37	653	96.0	132	22	AAU69907	M. tuberculosis pa
38	653	96.0	132	22	AAU69907	Mycobacterium tube
39	653	96.0	132	18	AAU69907	Mycobacterium tube
40	653	96.0	132	18	AAU69907	M. tuberculosis im
41	653	96.0	132	19	AAU69907	Mycobacterium tube
42	653	96.0	132	19	AAU69907	Mycobacterium tube
43	653	96.0	132	20	AAU69907	M. tuberculosis re
44	653	96.0	132	20	AAU69907	M. tuberculosis re
45	653	96.0	132	22	AAU69907	M. tuberculosis an

ALIGNMENTS

RESULT 1	AAU69899	standard; Protein; 224 AA.
XX	AAU69899	
AC	AAU69899	
XX	30-JAN-2002	(first entry)
XX	Human prostate protein/M. tuberculosis Ra12 fusion protein	
DE	Human prostate cancer; cytosolic; immunostimulant; tumour; immunogen;	
XX	Human; prostate cancer; cytosolic; immunostimulant; tumour; immunogen;	
KW	fusion protein.	
XX	Chimeric - Homo sapiens.	
OS	Chimeric - Microbacterium tuberculosis.	
OS	Synthetic.	
XX	MO200173032-A2.	
PN	04-OCT-2001.	
XX	04-OCT-2001.	
PD	04-OCT-2001.	
XX	27-MAR-2001; 2001MO-US09919.	
PF	27-MAR-2001; 2001MO-US09919.	
XX	27-MAR-2001; 2000US-0536857.	
PR	09-MAY-2000; 2000US-0568100.	
PR	12-MAY-2000; 2000US-0570737.	
PR	13-JUN-2000; 2000US-0593793.	
PR	17-JUN-2000; 2000US-0605783.	
PR	10-AUG-2000; 2000US-0636215.	
PR	29-AUG-2000; 2000US-0651236.	
PR	06-SEP-2000; 2000US-0657279.	
PR	02-OCT-2000; 2000US-0679426.	
PR	10-OCT-2000; 2000US-0685166.	
XX		

PA (CORI-) CORIXA CORP.

XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;
PI Fanger GR, Retter MM, Stolk JA, Day CH, Vedvick TS, Carter D;
PI Li SX, Wang A, Skelky YAW, Hepler WT, Henderson RA;
XX WPI; 2001-639232/73.
DR N-PSDB; AAS64132.

XX New human prostate-specific polypeptides and polynucleotides useful for
PT the diagnosis and treatment of cancer, especially prostate cancer - ,
XX

PS Example 17; Page 533-534; 579pp; English.

XX The invention relates to isolated prostate-specific
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,
CC antibodies raised against the polypeptides (or antigenic epitopes
CC derived from them) and antigen-presenting cells expressing the
CC polypeptides. The antibodies are useful for detecting the presence of
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and
CC T cells specific for a tumor protein, and for stimulating and/or expanding
CC of cancer especially prostate cancer. Compositions comprising the
CC polynucleotide and/or polypeptide are useful for stimulating an immune
CC response, and for treating cancer. The oligonucleotide is useful for
CC detecting cancer. The present sequence is fusion protein comprising a
CC prostate specific polypeptide of the invention.

XX Sequence 224 AA;

Query Match 100.0%; Score 653; DB 22; Length 224;
Best Local Similarity 100.0%; Pred. No. 1.2e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFQLSOGGOGFAIPICGAMAIAGQIKLPVHIGPTAFGLGVVNDNGNGARVQRV 60
Db |
8 taasdnfqlsoggogfaipicgamaiaagqiklpvhiptafglgvvndngngarvqr 67
QY 61 VGSAPASLIGSTGSDVITAVDGAPINSATAMADALNGHHPGDVISVTWOTKSGGTRTGNV 120
Db |
68 vgsapaslignstgsvitavdgapinsatamadalinghpgdvsvtwtksggtrtgnv 127

QY 121 TLAEGPPA 128
Db |
128 tlaegppa 135

RESULT 2

AA01254
ID AAM01254 standard; Protein; 224 AA.

XX AAM01254;

XX 04-OCT-2001 (first entry)

XX Ral2-P510S-C construct amino acid sequence.

XX Human; prostate cancer; prostate-specific; diagnosis; vaccine;
KW cytosolic; gene therapy; metastasis.

XX Homo sapiens.

XX WO200151633-A2.

XX 19-JUL-2001.

XX 16-JAN-2001; 2001WO-US01574.

XX 14-JAN-2000; 2000US-0483672.

XX (CORI-) CORIXA CORP.

PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
PI Kalos MD, Fanger GR, Day CH, Retter MM, Stolk JA, Skelky YAW;
PI Wang A, Meagher MJ;
XX WPI; 2001-425873/45.

XX New polynucleotide encoding a prostate-specific protein, for
PT diagnosing, monitoring and treating prostate cancer in a patient and
PT for use in vaccines -
XX

PS Claim 8; Page 493-494; 543pp; English.

XX The present invention describes polynucleotide sequences (I) which encode
CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,
CC and can be used in vaccine production and gene therapy. (I), (II),
CC antibodies to (II), fusion proteins comprising (II), and isolated
CC T cells prepared using (I) or (II) are used treat cancer in a patient.
CC (I) and the antibodies are also used in the detection of cancer in a
CC patient. The cancer that is diagnosed or treated is particularly
CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or
CC (I) can be used for monitoring the progression of cancer in a patient.
CC (I) and (II) can also be used to improve diagnostic and therapeutic
CC methods for prostate cancer. They can indicate the level of metastasis
CC as well as the prostate volume. AAH93357 to AAH93944 and AAM01115 to
CC AAM01318 represent polynucleotide and amino acid sequences used in the
CC exemplification of the present invention.

XX Sequence 224 AA;

Query Match 100.0%; Score 653; DB 22; Length 224;
Best Local Similarity 100.0%; Pred. No. 1.2e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFQLSOGGOGFAIPICGAMAIAGQIKLPVHIGPTAFGLGVVNDNGNGARVQRV 60
Db |
8 taasdnfqlsoggogfaipicgamaiaagqiklpvhiptafglgvvndngngarvqr 67
QY 61 VGSAPASLIGSTGSDVITAVDGAPINSATAMADALNGHHPGDVISVTWOTKSGGTRTGNV 120
Db |
68 vgsapaslignstgsvitavdgapinsatamadalinghpgdvsvtwtksggtrtgnv 127

QY 121 TLAEGPPA 128
Db |
128 tlaegppa 135

RESULT 3

AA069902
ID AA069902 standard; Protein; 304 AA.

XX AA069902;

XX 30-JAN-2002 (first entry)

XX Human /M. tuberculosis Ral2 fusion protein Ral2-P775P-ORF3.

XX Human; prostate cancer; cytosolic; immunostimulant; tumour; immunogen;
KW fusion protein.

XX Chimeric - Homo sapiens.

XX Chimeric - Microbacterium tuberculosis.

XX WO200173032-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09919.

XX 27-MAR-2000; 2000US-0536857.

XX 09-MAY-2000; 2000US-0568100.

XX 12-MAY-2000; 2000US-0570737.

1

PR 13-JUN-2000; 2000US-0539793.
PR 27-JUN-2000; 2000US-0605783.
PR 10-AUG-2000; 2000US-0636215.
PR 29-AUG-2000; 2000US-0651236.
PR 06-SEP-2000; 2000US-0657279.
PR 02-OCT-2000; 2000US-0679426.
PR 10-OCT-2000; 2000US-0685166.
XX
XX (CORI-) CORIXA CORP.
XX
XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;
PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedvick TS, Carter D;
PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;
XX
XX WPI: 2001-639232/773.
DR N-PDSB; AAS64141.
XX
XX New human prostate-specific polypeptides and polynucleotides useful for
PT the diagnosis and treatment of cancer, especially prostate cancer -
PS
PS Example 17; Page 537; 579pp; English.
XX
XX The invention relates to isolated prostate-specific
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,
CC antibodies raised against the polypeptides (or antigenic epitopes
CC derived from them) and antigen-presenting cells expressing the
CC polypeptides. The antibodies are useful for detecting the presence of
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and
CC the antigen-presenting cells are useful for stimulating and/or expanding
CC T cells specific for a tumour protein, and for inhibiting the development
CC of cancer especially prostate cancer. Compositions comprising the
CC polynucleotide and/or polypeptide are useful for stimulating an immune
CC response, and for treating cancer. The oligonucleotide is useful for
CC detecting cancer. The present sequence is fusion protein comprising a
CC prostate specific polypeptide of the invention.
XX
SQ Sequence 304 AA;

Query Match 100.0%; Score 653; DB 22; Length 304;
Best Local Similarity 100.0%; Pred. No. 1.8e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAAADNFQLSGGGCGFAIPIGQAMAIAGQIKLPYHIGTAFGLGVNDNGNGARVORY 60
DB 8 taasdnfqlsggggqfaipigqamalaagqiklpvnhgptafglgvndnngarvqr 67
QY 61 VGSAPPAASIGISTGDIYTVAVDGPINSATAMADALNGHHGPDVISTWQTKSGGTRTCNV 120
DB 68 vgsapapaasigistgdvltavdgapinsatamadalnghhpgdvistwqtksggtrtgnv 127

QY 121 TLAEGPPA 128
DB 128 tlaegppa 135

RESULT 4
AAM01257
ID AAM01257 standard; Protein; 304 AA.
XX
XX AAM01257;
AC
XX
XX 04-OCT-2001 (first entry)
DT
XX
XX RAI2-P775P-ORF3 construct amino acid sequence.
DE
XX
XX Human: prostate cancer; prostate-specific; diagnosis; vaccine;
KW cytostatic; gene therapy; metastasis.
XX
XX Homo sapiens.
OS
XX
XX WO200151633-A2.
PN
XX

PD 19-JUL-2001.
XX
XX 16-JAN-2001; 2001WO-US01574.
PF
XX
XX 14-JAN-2000; 2000US-0483672.
PR
XX
XX (CORI-) CORIXA CORP.
XX
XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
PI Kalos MD, Fanger GR, Day CH, Retter MW, Stolk JA, Skeiky YAW;
PI Wang A, Meagher MJ;
XX
XX WPI: 2001-425873/45.
DR
XX
XX New polynucleotide encoding a prostate-specific protein, for
PT diagnosing, monitoring and treating prostate cancer in a patient and
PT for use in vaccines -
PS
PS Claim 8; Page 498-499; 543pp; English.
XX
XX The present invention describes polynucleotide sequences (I) which encode
CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,
CC and can be used in vaccine production and gene therapy. (I), (II),
CC antibodies to (II), fusion proteins comprising (II), and isolated
CC T cells prepared using (I) or (II) are used to treat cancer in a patient.
CC (I) and the antibodies are also used in the detection of cancer in a
CC patient. The cancer that is diagnosed or treated is particularly
CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or
CC (I) can be used for monitoring the progression of cancer in a patient.
CC (I) and (II) can also be used to improve diagnostic and therapeutic
CC methods for prostate cancer. They can indicate the level of metastasis
CC as well as the prostate volume. AAH93357 to AAH93944 and AAM01115 to
CC AAM01318 represent polynucleotide and amino acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 304 AA;

Query Match 100.0%; Score 653; DB 22; Length 304;
Best Local Similarity 100.0%; Pred. No. 1.8e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAAADNFQLSGGGCGFAIPIGQAMAIAGQIKLPYHIGTAFGLGVNDNGNGARVORY 60
DB 8 taasdnfqlsggggqfaipigqamalaagqiklpvnhgptafglgvndnngarvqr 67
QY 61 VGSAPPAASIGISTGDIYTVAVDGPINSATAMADALNGHHGPDVISTWQTKSGGTRTCNV 120
DB 68 vgsapapaasigistgdvltavdgapinsatamadalnghhpgdvistwqtksggtrtgnv 127

QY 121 TLAEGPPA 128
DB 128 tlaegppa 135

RESULT 5
AAU69907
ID AAU69907 standard; Protein; 400 AA.
XX
XX AAU69907;
AC
XX
XX 30-JAN-2002 (first entry)
DT
XX
XX Human prostate protein/M. tuberculosis RAI2 fusion protein RAI2-P501S-E2.
DE
XX
XX Human: prostate cancer; cytostatic; immunostimulant; tumour; immunogen;
KW fusion protein.
XX
XX Chimeric - Homo sapiens.
OS
XX
XX Chimeric - Microbacterium tuberculosis.
OS
XX
XX WO200173032-A2.
PN
XX

PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09919.
 XX
 PR 27-MAR-2000; 2000US-0536857.
 PR 09-MAY-2000; 2000US-0568100.
 PR 12-MAY-2000; 2000US-0570737.
 PR 13-JUN-2000; 2000US-0593793.
 PR 27-JUN-2000; 2000US-0605783.
 PR 10-AUG-2000; 2000US-0636215.
 PR 29-AUG-2000; 2000US-0651236.
 PR 06-SEP-2000; 2000US-0657279.
 PR 02-OCT-2000; 2000US-0679426.
 PR 10-OCT-2000; 2000US-0685166.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;
 PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedvick TS, Carter D;
 PI Li SX, Wang A, Skeiky YAM, Hepler WT, Henderson RA;
 XX
 DR WPI: 2001-639232/73.
 DR N-PSDB; AAS64153.
 XX
 PT New human prostate-specific polypeptides and polynucleotides useful for
 PT the diagnosis and treatment of cancer, especially prostate cancer -
 XX
 PS Example 17; Page 543-544; 579pp; English.
 XX
 CC The invention relates to isolated prostate-specific
 CC polynucleotides, polypeptides, fusion proteins of the polypeptides,
 CC antibodies raised against the polypeptides (or antigenic epitopes
 CC derived from them) and antigen-presenting cells expressing the
 CC polypeptides. The antibodies are useful for detecting the presence of
 CC cancer, especially prostate cancer. The polypeptides, polynucleotides and
 CC T cells specific for a tumor protein, and for inhibiting the development
 CC of cancer especially prostate cancer. Compositions comprising the
 CC polynucleotide and/or polypeptide are useful for stimulating an immune
 CC response, and for treating cancer. The oligonucleotide is useful for
 CC detecting cancer. The present sequence is fusion protein comprising a
 CC prostate specific polypeptide of the invention.
 CC
 XX
 SQ Sequence 400 AA;
 Query Match 100.0%; Score 653; DB 22; Length 400;
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFQLSGGGGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVVNNNGARVQRY 60
 Db 8 taasdnfqlsggggfaipigqamaisgqiklpvhiptafglgvvnnngarvqr 67
 QY 61 VGSAPASLSIGTSDVITAVDGAIPINSATAMADALNGHHPEVDVSYVMQTKSGGTRGNV 120
 Db 68 vgsapaalsigtsgdvtavdgapinsatamadalnghhpgdivsvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 6
 AAM01262
 ID AAM01262 standard; Protein; 400 AA.
 AC AAM01262;
 XX
 XX
 DT 04-OCT-2001 (first entry)
 XX
 DE Ral2-P501S-E2 construct amino acid sequence.
 XX

4

KW Human: prostate cancer; prostate-specific; diagnosis; vaccine;
 KW cytostatic; gene therapy; metastasis.
 OS Homo sapiens.
 XX
 XX WO200151633-A2.
 XX
 PD 19-JUL-2001.
 XX
 XX 16-JAN-2001; 2001WO-US01574.
 XX
 XX 14-JAN-2000; 2000US-0483672.
 XX
 XX
 XX (CORI-) CORIXA CORP.
 XX
 PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
 PI Kalos MD, Fanger GR, Day CH, Retter MW, Stolk JA, Skeiky YAM;
 PI Wang A, Meagher MJ;
 XX
 DR WPI: 2001-425873/45.
 XX
 PT New polynucleotide encoding a prostate-specific protein, for
 PT diagnosing, monitoring and treating prostate cancer in a patient and
 PT for use in vaccines -
 XX
 PS Claim 8; Page 504-506; 543pp; English.
 XX
 CC The present invention describes polynucleotide sequences (I) which encode
 CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,
 CC and can be used in vaccine production and gene therapy. (I), (II),
 CC antibodies to (II), fusion proteins comprising (II), and isolated
 CC T cells prepared using (I) or (II) are used treat cancer in a patient.
 CC (I) and the antibodies are also used in the detection of cancer in a
 CC patient. The cancer that is diagnosed or treated is particularly
 CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or
 CC (I) and (II) can be used for monitoring the progression of cancer in a patient.
 CC methods for prostate cancer. They can indicate the level of metastasis
 CC as well as the prostate volume. AAH93357 to AAH93944 and AAM01115 to
 CC AAM01318 represent polynucleotide and amino acid sequences used in the
 CC exemplification of the present invention.
 CC
 XX
 SQ Sequence 400 AA;
 Query Match 100.0%; Score 653; DB 22; Length 400;
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFQLSGGGGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVVNNNGARVQRY 60
 Db 8 taasdnfqlsggggfaipigqamaisgqiklpvhiptafglgvvnnngarvqr 67
 QY 61 VGSAPASLSIGTSDVITAVDGAIPINSATAMADALNGHHPEVDVSYVMQTKSGGTRGNV 120
 Db 68 vgsapaalsigtsgdvtavdgapinsatamadalnghhpgdivsvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 Db 128 tlaegppa 135

RESULT 7
 AAG83280
 ID AAG83280 standard; Protein; 487 AA.
 AC AAG83280;
 XX
 XX
 DT 05-SEP-2001 (first entry)
 XX
 DE Chlamydia trachomatis PmpC(1) fusion protein.
 XX
 KW Chlamydia; vaccine; infection; fusion protein; antigen;

KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KM acute respiratory tract infection; Cap1; CT529; OMCB;
 XX polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX Chlamydia trachomatis.
 OS
 PN WO200140474-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 04-DEC-2000; 2000WO-US32919.
 XX
 PR 03-DEC-1999; 99US-0454684.
 PR 19-APR-2000; 2000US-0556877.
 PR 20-JUN-2000; 2000US-0598419.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;
 XX
 DR WPI; 2001-374831/39.
 XX
 PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX
 PS Claim 70; Page 289-290; 295pp; English.
 XX
 CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 CC
 XX
 SQ Sequence 487 AA;
 XX
 Query Match 100.0%; Score 653; DB 22; Length 487;
 Best Local Similarity 100.0%; Pred. No. 3.2e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFQLSGGCGFAIPRIGQAMAIAGQIKLPYHIGFATLGLGVNDNGARVQRV 60
 DB 8 taasdnfqlsggqgqgfaipligqamaiaqiklpvhiqfataflgylvvndnngarvqr 67
 QY 61 VGSAPAAASIGISTGVITAVDGCAPINSATAMADALNGHHRGDVISVTWOTKSGGRTGNV 120
 DB 68 vgsapaasligistgvtavdgcapinsatamadalinghnpdvisvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 DB 128 tlaegppa 135
 XX
 RESULT 8
 AAG83276
 ID AAG83276 standard; Protein; 518 AA.
 XX
 AC AAG83276;
 XX
 DT 05-SEP-2001 (first entry)
 XX
 DE Chlamydia trachomatis PmpB(1) fusion protein.
 XX
 KM Chlamydia; vaccine; infection; fusion protein; antigen;
 KM pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KM acute respiratory tract infection; Cap1; CT529; OMCB;
 KM polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX
 OS Chlamydia trachomatis.

XX
 PN WO200140474-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 04-DEC-2000; 2000WO-US32919.
 XX
 PR 03-DEC-1999; 99US-0454684.
 PR 19-APR-2000; 2000US-0556877.
 PR 20-JUN-2000; 2000US-0598419.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;
 XX
 DR WPI; 2001-374831/39.
 XX
 PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 PT inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 XX
 PS Claim 70; Page 279-280; 295pp; English.
 XX
 CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of chlamydial
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against chlamydial infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 CC
 XX
 SQ Sequence 518 AA;
 XX
 Query Match 100.0%; Score 653; DB 22; Length 518;
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAASDNFQLSGGCGFAIPRIGQAMAIAGQIKLPYHIGFATLGLGVNDNGARVQRV 60
 DB 8 taasdnfqlsggqgqgfaipligqamaiaqiklpvhiqfataflgylvvndnngarvqr 67
 QY 61 VGSAPAAASIGISTGVITAVDGCAPINSATAMADALNGHHRGDVISVTWOTKSGGRTGNV 120
 DB 68 vgsapaasligistgvtavdgcapinsatamadalinghnpdvisvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 DB 128 tlaegppa 135
 XX
 RESULT 9
 AAB13645
 ID AAB13645 standard; Protein; 525 AA.
 XX
 AC AAB13645;
 XX
 DT 02-FEB-2001 (first entry)
 XX
 DE C. pneumoniae serovar MOMP pmp gene Ra12 fusion protein.
 XX
 KM Chlamydial infection; sexually transmitted disease;
 KM pelvic inflammatory disease; PID; tubal obstruction; infertility;
 KM trachoma; blindness; acute respiratory tract infection;
 KM atherosclerosis; coronary heart disease; antibacterial.
 XX
 OS Chlamydia pneumoniae.
 XX
 PN WO200034483-A2.
 XX
 PD 15-JUN-2000.

PF 08-DEC-1999; 99WO-US29012.
 XX
 PR 08-DEC-1998; 98US-0208277.
 PR 08-APR-1999; 99US-0288594.
 PR 01-OCT-1999; 99US-0410568.
 PR 22-OCT-1999; 99US-0426571.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Jen S, Stromberg EJ,
 XX WPL; 2000-431303/37.
 XX
 PT Isolated polypeptide for diagnosis and treatment of Chlamydia infection
 PT comprises immunogenic portion of Chlamydia antigen, which comprises
 XX amino acid sequence encoded by polynucleotide sequence -
 PS
 PS Claim 2; Pages 221-222; 256pp; English.
 XX
 CC The present invention relates to new nucleic acid sequences and the
 CC proteins encoded by the nucleic acid sequences. The encoded proteins
 CC comprise an immunogenic portion of a Chlamydia antigen. The encoded
 CC proteins are useful for the serodiagnosis and treatment of Chlamydia
 CC infection. Chlamydiae are intracellular bacterial pathogens that are
 CC responsible for a wide variety of human infections. C. trachomatis
 CC infection is one of the most common sexually transmitted diseases and can
 CC lead to pelvic inflammatory disease (PID), resulting in tubal obstruction
 CC and infertility. Trachoma due to ocular infection with C. trachomatis is
 CC the leading cause of preventable blindness worldwide. C. pneumonia is a
 CC major cause of acute respiratory tract infections in humans and is also
 CC thought to play a role in the pathogenesis of atherosclerosis and
 CC coronary heart disease. The present sequence is a protein isolated in the
 CC present invention.
 CC
 XX Sequence 525 AA;
 SQ

Query Match 100.0%; Score 653; DB 21; Length 525;
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGGGFAIPIGQAMAIAGQIKLPVTHIGPTAFGLGVVDNNGGARVORV 60
 Db |||||||
 8 taasdnfqlsggggfaipigqamaiaqgiklpvthigptafglgvvdnnggarvgrv 67
 QY 61 VGSAPAAASLGISTGSDVITAVDGPAINSATAMADALNGHHHPGDVIVSWOTKSGGTRTGNV 120
 Db |||||||
 68 vgsapaaslgistgsvitavdgapinsatamadalinghpgdivisvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 Db |||||||
 128 tlaegppa 135

RESULT 10
 AAG83213
 ID AAG83213 standard; Protein; 525 AA.
 AC
 XX AAG83213;
 XX

DT 05-SEP-2001 (first entry)
 XX

DE Protein encoded by Chlamydia trachomatis serovar MOMPS pmp gene.
 XX

KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KW acute respiratory tract infection; Cap1; CT529; OMCB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX
 OS Chlamydia trachomatis.
 XX
 PN WO200140474-A2.
 XX

PD 07-JUN-2001.
 XX
 XX 04-DEC-2000; 2000WO-US32919.
 PF
 XX
 PR 03-DEC-1999; 99US-0454684.
 PR 19-APR-2000; 2000US-0556877.
 PR 20-JUN-2000; 2000US-0598419.
 XX
 PA (CORI-) CORIXA CORP.
 XX
 PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;
 XX WPL; 2001-374831/39.
 XX
 DR Chlamydia polypeptides and fusion proteins useful for preventing pelvic
 XX inflammatory disease, trachoma, acute respiratory tract infections,
 PT atherosclerosis and heart disease -
 PS
 PS Claim 2; Page 226-227; 295pp; English.
 XX
 CC The present sequence is provided in a specification relating to
 CC compounds and methods for the treatment and diagnosis of Chlamydia
 CC infection. The compounds provided include polypeptides and fusion
 CC proteins comprising immunogenic portions of Chlamydia antigens
 CC and DNA sequences encoding such polypeptides. They are useful for
 CC vaccinating against Chlamydia infection, which causes pelvic
 CC inflammatory disease, trachoma, acute respiratory tract infections,
 CC atherosclerosis and heart disease.
 CC
 XX Sequence 525 AA;
 SQ

Query Match 100.0%; Score 653; DB 22; Length 525;
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGGGFAIPIGQAMAIAGQIKLPVTHIGPTAFGLGVVDNNGGARVORV 60
 Db |||||||
 8 taasdnfqlsggggfaipigqamaiaqgiklpvthigptafglgvvdnnggarvgrv 67
 QY 61 VGSAPAAASLGISTGSDVITAVDGPAINSATAMADALNGHHHPGDVIVSWOTKSGGTRTGNV 120
 Db |||||||
 68 vgsapaaslgistgsvitavdgapinsatamadalinghpgdivisvtwtksggtrtgnv 127
 QY 121 TLAEGPPA 128
 Db |||||||
 128 tlaegppa 135

RESULT 11
 AAG83281
 ID AAG83281 standard; Protein; 583 AA.
 AC
 XX AAG83281;
 XX

DT 05-SEP-2001 (first entry)
 XX

DE Chlamydia trachomatis PmpC(2) fusion protein.
 XX

KW Chlamydia; vaccine; infection; fusion protein; antigen;
 KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 KW acute respiratory tract infection; Cap1; CT529; OMCB;
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
 XX
 OS Chlamydia trachomatis.
 XX
 PN WO200140474-A2.
 XX

PD 07-JUN-2001.
 XX
 XX 04-DEC-2000; 2000WO-US32919.
 PF
 XX 03-DEC-1999; 99US-0454684.
 PR

PR 19-APR-2000; 2000US-0556877.
PR 20-JUN-2000; 2000US-0598419.
XX
PA (CORI-) CORIXA CORP.
PI Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;
XX WPI; 2001-374831/39.
DR
XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic
PT inflammatory disease, trachoma, acute respiratory tract infections,
PT atherosclerosis and heart disease -
XX
XX
PS Claim 70; Page 291-292; 295pp; English.
XX
CC The present sequence is provided in a specification relating to
CC compounds and methods for the treatment and diagnosis of chlamydial
CC infection. The compounds provided include polypeptides and fusion
CC proteins comprising immunogenic portions of Chlamydia antigens
CC and DNA sequences encoding such polypeptides. They are useful for
CC vaccinating against chlamydial infection, which causes pelvic
CC inflammatory disease, trachoma, acute respiratory tract infections,
CC atherosclerosis and heart disease.
XX
SQ Sequence 583 AA;

Query Match 100.0%; Score 653; DB 22; Length 583;
Best Local Similarity 100.0%; Pred. No. 4e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPGQAMAIAGQIKLPVHIGPTAFGLGVNDNNGARVQRY 60
Db 8 taasdnfqlsgggqgfalpigqamaiaqiklpvhiqptafllgvyvndnngarvqr 67
OY 61 VGSAPAAISGISTGVITAVDCAPINSATAMADALNGHHPGDIIVTWQTKSGGRTGNV 120
Db 68 vgsapaaslgistgvtavdgapinsatamadalnghhpqdvistwtqtksggrrtgnv 127

OY 121 TLAEGPPA 128
Db 128 tlaegppa 135

RESULT 12

AAG83277
ID AAG83277 standard; Protein; 585 AA.

XX AAG83277;

DT 05-SEP-2001 (first entry)

XX Chlamydia trachomatis PmpB(2) fusion protein.

XX Chlamydia: vaccine; infection; fusion protein; antigen;
KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
KW acute respiratory tract infection; Cap1; CT529; OMCB;
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
XX
OS Chlamydia trachomatis.

XX WO200140474-A2.

PD 07-JUN-2001.

PF 04-DEC-2000; 2000WO-US32919.

XX 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

PI Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;
XX WPI; 2001-374831/39.
DR
XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic
PT inflammatory disease, trachoma, acute respiratory tract infections,
PT atherosclerosis and heart disease -
XX
XX
PS Claim 70; Page 282-283; 295pp; English.
XX
CC The present sequence is provided in a specification relating to
CC compounds and methods for the treatment and diagnosis of chlamydial
CC infection. The compounds provided include polypeptides and fusion
CC proteins comprising immunogenic portions of Chlamydia antigens
CC and DNA sequences encoding such polypeptides. They are useful for
CC vaccinating against chlamydial infection, which causes pelvic
CC inflammatory disease, trachoma, acute respiratory tract infections,
CC atherosclerosis and heart disease.
XX
SQ Sequence 585 AA;

Query Match 100.0%; Score 653; DB 22; Length 585;
Best Local Similarity 100.0%; Pred. No. 4.1e-60;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPGQAMAIAGQIKLPVHIGPTAFGLGVNDNNGARVQRY 60
Db 8 taasdnfqlsgggqgfalpigqamaiaqiklpvhiqptafllgvyvndnngarvqr 67
OY 61 VGSAPAAISGISTGVITAVDCAPINSATAMADALNGHHPGDIIVTWQTKSGGRTGNV 120
Db 68 vgsapaaslgistgvtavdgapinsatamadalnghhpqdvistwtqtksggrrtgnv 127

OY 121 TLAEGPPA 128
Db 128 tlaegppa 135

RESULT 13

AAG83270
ID AAG83270 standard; Protein; 619 AA.

XX AAG83270;

DT 05-SEP-2001 (first entry)

XX Chlamydia trachomatis PmpA(N-term) fusion protein.

XX Chlamydia: vaccine; infection; fusion protein; antigen;
KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
KW acute respiratory tract infection; Cap1; CT529; OMCB;
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.
XX
OS Chlamydia trachomatis.

XX WO200140474-A2.

PD 07-JUN-2001.

PF 04-DEC-2000; 2000WO-US32919.

XX 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

XX Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;

DR WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

22

CC and DNA sequences encoding such polypeptides. They are useful for

QY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGNGARVQRY 60
 |||||
 Db 8 taasdnfqlsggggfaipigqamalaqgiklpvthigpafglgvdnngngarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120
 |||||
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtsqgtrtgnv 127

QY 121 TLAEGPPA 128
 |||||
 Db 128 tlaegppa 135

RESULT 18

AAG83271
 ID AAG83271 standard; Protein: 691 AA.

AC AAG83271;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpA(C-term) fusion protein.

KW Chlamydia; vaccine; infection; fusion protein; antigen;

KM pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 acute respiratory tract infection; Cap1; CT529; OMCB;

KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

XX Chlamydia trachomatis.

PN W0200140474-A2.

PD 07-JUN-2001.

PE 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

DR WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

PT inflammatory disease, trachoma, acute respiratory tract infections,

PT atherosclerosis and heart disease -

PS Claim 70; Page 267-268; 295pp; English.

XX The present sequence is provided in a specification relating to

CC compounds and methods for the treatment and diagnosis of chlamydial

CC infection. The compounds provided include polypeptides and fusion

CC proteins comprising immunogenic portions of Chlamydia antigens

CC and DNA sequences encoding such polypeptides. They are useful for

CC vaccinating against chlamydial infection, which causes pelvic

CC inflammatory disease, trachoma, acute respiratory tract infections,

CC atherosclerosis and heart disease.

XX Sequence 691 AA;

Query Match 100.0%; Score 653; DB 22; Length 691;

Best Local Similarity 100.0%; Pred. No. 5e-60; Mismatches 0; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGNGARVQRY 60
 |||||
 Db 8 taasdnfqlsggggfaipigqamalaqgiklpvthigpafglgvdnngngarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120
 |||||
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtsqgtrtgnv 127

QY 121 TLAEGPPA 128
 |||||
 Db 128 tlaegppa 135

RESULT 19

AAG83279
 ID AAG83279 standard; Protein: 700 AA.

AC AAG83279;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpB(4) fusion protein.

KW Chlamydia; vaccine; infection; fusion protein; antigen;

KM pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
 acute respiratory tract infection; Cap1; CT529; OMCB;

KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

XX Chlamydia trachomatis.

PN W0200140474-A2.

PD 07-JUN-2001.

PE 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

DR WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

PT inflammatory disease, trachoma, acute respiratory tract infections,

PT atherosclerosis and heart disease -

PS Claim 70; Page 286-288; 295pp; English.

XX The present sequence is provided in a specification relating to

CC compounds and methods for the treatment and diagnosis of chlamydial

CC infection. The compounds provided include polypeptides and fusion

CC proteins comprising immunogenic portions of Chlamydia antigens

CC and DNA sequences encoding such polypeptides. They are useful for

CC vaccinating against chlamydial infection, which causes pelvic

CC inflammatory disease, trachoma, acute respiratory tract infections,

CC atherosclerosis and heart disease.

XX Sequence 700 AA;

Query Match 100.0%; Score 653; DB 22; Length 700;

Best Local Similarity 100.0%; Pred. No. 5.1e-60; Mismatches 0; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGNGARVQRY 60
 |||||
 Db 8 taasdnfqlsggggfaipigqamalaqgiklpvthigpafglgvdnngngarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120
 |||||
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtsqgtrtgnv 127

QY 121 TLAEGPPA 128

Job 128 tlaegppa 135

RESULT 20

AA83273 standard; Protein; 715 AA.

AA83273;

05-SEP-2001 (first entry)

Chlamydia trachomatis PmpF(C-term) fusion protein.

Chlamydia; vaccine; infection; fusion protein; antigen;
pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
acute respiratory tract infection; CapI; CT529; OMCB;
polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

Chlamydia trachomatis.

MO200140474-A2.

07-JUN-2001.

04-DEC-2000; 2000MO-US32919.

03-DEC-1999; 99US-0454684.

19-APR-2000; 2000US-0556877.

20-JUN-2000; 2000US-0598419.

(CORI-) CORIXA CORP.

Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;

WPI; 2001-374831/39.

Chlamydia polypeptides and fusion proteins useful for preventing pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease -

Claim 70; Page 272-273; 295pp: English.

The present sequence is provided in a specification relating to

compounds and methods for the treatment and diagnosis of chlamydial

infection. The compounds provided include polypeptides and fusion

proteins comprising immunogenic portions of Chlamydia antigens

and DNA sequences encoding such polypeptides. They are useful for

vaccinating against chlamydial infection, which causes pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease.

Sequence 715 AA;

Query Match 100.0%; Score 653; DB 22; Length 715;

Best Local Similarity 100.0%; Pred. No. 5.2e-60; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 21

AA83275 standard; Protein; 715 AA.

AA83275;

05-SEP-2001 (first entry)

Chlamydia trachomatis PmpF(C-term) fusion protein.

Chlamydia; vaccine; infection; fusion protein; antigen;
pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;
acute respiratory tract infection; CapI; CT529; OMCB;
polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

Chlamydia trachomatis.

MO200140474-A2.

07-JUN-2001.

04-DEC-2000; 2000MO-US32919.

03-DEC-1999; 99US-0454684.

19-APR-2000; 2000US-0556877.

20-JUN-2000; 2000US-0598419.

(CORI-) CORIXA CORP.

Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;

WPI; 2001-374831/39.

Chlamydia polypeptides and fusion proteins useful for preventing pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease -

Claim 70; Page 277-278; 295pp: English.

The present sequence is provided in a specification relating to

compounds and methods for the treatment and diagnosis of chlamydial

infection. The compounds provided include polypeptides and fusion

proteins comprising immunogenic portions of Chlamydia antigens

and DNA sequences encoding such polypeptides. They are useful for

vaccinating against chlamydial infection, which causes pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease.

Sequence 715 AA;

Query Match 100.0%; Score 653; DB 22; Length 715;

Best Local Similarity 100.0%; Pred. No. 5.2e-60; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Search completed: August 14, 2002, 09:40:53

Job time: 40 sec

